Fate Therapeutics, Inc.
NASDAQ: FATE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bahram Valamehr
- Employees
- 181
- Headquarters
- San Diego, United States
- IPO year
- 2013
- Market cap
- $240.1M
- Website
- https://www.fatetherapeutics.com
Loading FATE…
Loading profile data…Frequently asked questions about FATE
What does Fate Therapeutics, Inc. (FATE) do?
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs....
Where does FATE trade?
Fate Therapeutics, Inc. (FATE) trades on the NASDAQ Global Market.
What sector is FATE in?
Fate Therapeutics, Inc. (FATE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Fate Therapeutics, Inc.?
Bahram Valamehr is the chief executive officer of Fate Therapeutics, Inc. (FATE).
Where is Fate Therapeutics, Inc. headquartered?
Fate Therapeutics, Inc. is headquartered in United States.
Does FATE pay a dividend?
Fate Therapeutics, Inc. (FATE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FATE go public?
Fate Therapeutics, Inc. (FATE) completed its initial public offering in 2013.